W35--Navigating GI & Hepatic Challenges in CF: Current Insights & Future Directions
W35.1- Hepatobiliary abnormalities and change in serum and imaging biomarkers in young children with CF before and after 12 months of elexacaftor/tezacaftor/ivacaftor: Interim Results from the BEGIN Study